Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of blood cancers originating in the lymphatic system, distinguished from Hodgkin’s lymphoma by the absence of Reed-Sternberg cells. Globally, NHL represents nearly 45% of all lymphoma cases, with a higher incidence among older adults. According to the non-Hodgkin’s lymphoma pipeline analysis by Expert Market Research, the drug pipeline encompasses monoclonal antibodies, small molecules, gene therapies, and cell-based therapies targeting both aggressive and indolent subtypes. Increasing focus on immunotherapies and targeted treatments, coupled with rising prevalence, aging populations, and unmet medical needs, is expected to drive significant growth in NHL therapeutics in the coming years.
-
Major companies involved in the non-Hodgkin’s lymphoma pipeline analysis include Sichuan Baili Pharmaceutical Co., Ltd., Beijing Mabworks Biotech Co., Ltd., and others.
-
Leading drugs currently in the pipeline include GNC-038, MBS303, N803, and others.
-
The pipeline shows robust growth driven by targeted therapies, including CAR-T and bispecific antibodies, alongside increasing clinical trials focusing on personalized and combination treatment approaches for improved patient outcomes.
Report Coverage
The Non-Hodgkin’s Lymphoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into Non-Hodgkin’s lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for non-Hodgkin’s lymphoma. The Non-Hodgkin’s lymphoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Non-Hodgkin’s lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Non-Hodgkin’s lymphoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to non-Hodgkin’s lymphoma.
Read more about this report - Request a Free Sample
Non-Hodgkin’s Lymphoma Pipeline Outlook
Non-Hodgkin’s lymphoma is a blood cancer originating in the lymphatic system, affecting B-cells or T-cells. It develops when abnormal lymphocytes grow uncontrollably, forming tumors in lymph nodes, spleen, or other organs, often causing fatigue, swollen lymph nodes, fever, and recurrent infections.
Non-Hodgkin’s lymphoma treatments include chemotherapy, targeted therapy, immunotherapy, radiation, and stem cell transplantation to eliminate cancer cells and control disease progression. In June 2025, zanubrutinib (Brukinsa®) was approved in the UK as a treatment for relapsed or refractory mantle cell lymphoma. This oral Bruton tyrosine kinase inhibitor provides patients with an effective, convenient, home-based therapy option, reducing hospital visits.
Non-Hodgkin’s Lymphoma Epidemiology
Non-Hodgkin lymphoma (NHL) represents nearly 45% of all lymphoma cases, with the majority (85–90%) arising from B cells and the remainder from T cells or natural killer cells, as reported by Xiaobo Luo et al., 2025. In 2021, NHL contributed to approximately 962,474 disability-adjusted life years (DALYs) globally, with an age-standardized death rate (ASDR) of 13.535 per 100,000. South Asia experienced the highest regional DALYs, while Australasia reported the lowest. Eastern Sub-Saharan Africa had the highest ASDR, and High-Income North America the lowest. From 1990–2021, Southern Sub-Saharan Africa showed the largest ASDR increase, contrasted by a significant decrease in East Asia.
Non-Hodgkin’s Lymphoma – Pipeline Therapeutic Assessment
This section of the report covers the analysis of non-Hodgkin’s lymphoma drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The non-Hodgkin’s lymphoma pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Peptides
- Cell Therapies
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Non-Hodgkin’s Lymphoma Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total Non-Hodgkin’s lymphoma clinical trials, accounts for 50% of developments. It is followed by phase II at 40%. The strong focus on early and mid-phase studies indicates robust innovation, which can drive the introduction of effective therapies and positively impact market growth.
Non-Hodgkin’s Lymphoma Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the Non-Hodgkin’s lymphoma pipeline analysis include small molecules, monoclonal antibodies, peptides, and cell therapies. The Non-Hodgkin’s lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for non-Hodgkin’s lymphoma. Targeted combination therapies are gaining attention in the non-Hodgkin’s lymphoma drug pipeline to improve treatment outcomes. For example, the ViPOR regimen, a five-drug combination including venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, is under Phase Ib/II evaluation for relapsed or refractory diffuse large B-cell lymphoma. This approach targets multiple molecular pathways to enhance tumor reduction and improve patient response rates.
Non-Hodgkin’s Lymphoma Clinical Trials – Key Players
The EMR report for the Non-Hodgkin’s lymphoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Non-Hodgkin’s lymphoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in non-Hodgkin’s lymphoma clinical trials:
- Sichuan Baili Pharmaceutical Co., Ltd.
- Beijing Mabworks Biotech Co., Ltd.
- ImmunityBio, Inc.
- Shanghai Junshi Bioscience Co., Ltd.
- Estrella Biopharma, Inc.
- AbbVie
- Sana Biotechnology
- Hoffmann-La Roche
- Regeneron Pharmaceuticals
- Hrain Biotechnology Co., Ltd.
- Nanjing IASO Biotechnology Co., Ltd.
- Ascentage Pharma Group Inc.
Non-Hodgkin’s Lymphoma – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for non-Hodgkin’s lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of non-Hodgkin’s lymphoma drug candidates.
Drug: GNC-038
GNC-038 is an octavalent, tetra-specific antibody being developed by Sichuan Baili Pharmaceutical Co., Ltd. for patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL). The drug functions as a CD19-specific T cell engager, simultaneously targeting PD-L1 and 4-1BB to activate T cells and directly attack malignant cells. Administered via intravenous infusion once weekly, GNC-038 is currently in a Phase Ib/II study exploring its safety, tolerability, pharmacokinetics, and antitumor activity. The Phase Ib portion is determining the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D), while Phase II is assessing preliminary efficacy in NHL patients. Preclinical studies indicate strong anti-tumor activity and favorable pharmacokinetics.
Drug: MBS303
MBS303 is an innovative CD20/CD3 T-cell engager being developed by Beijing Mabworks Biotech Co., Ltd. This Phase I/II study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of MBS303 administered via intravenous infusion in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. MBS303 functions by redirecting T-cells to selectively target and eliminate CD20-positive B-cells, enhancing immune-mediated tumor destruction. The study is structured with a dose-escalation Phase I followed by a Phase II expansion, aiming to identify optimal dosing and preliminary therapeutic benefit. Results are expected to guide future clinical development.
Drug: N803
CD19 t-haNK, sponsored by ImmunityBio, Inc., is undergoing a Phase 1, first-in-human study to evaluate its safety as a single agent and in combination with rituximab, with or without the IL-15 superagonist N-803, in subjects with relapsed or refractory Non-Hodgkin’s Lymphoma (R/R NHL). This open-label study is examining the drug’s safety, tolerability, and preliminary efficacy through intravenous administration following lymphodepleting chemotherapy. CD19 t-haNK is an engineered natural killer cell therapy targeting CD19-positive B cells, while N-803 stimulates proliferation of NK and T cells, enhancing the immune response. Up to 20 subjects are being enrolled to assess safety and preliminary efficacy.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Non-Hodgkin’s Lymphoma Pipeline Insight Report
- Which companies/institutions are leading the Non-Hodgkin’s lymphoma drug development?
- Which company is leading the Non-Hodgkin’s lymphoma pipeline development activities?
- What is the current Non-Hodgkin’s lymphoma commercial assessment?
- What are the opportunities and challenges present in the Non-Hodgkin’s lymphoma pipeline landscape?
- What is the efficacy and safety profile of Non-Hodgkin’s lymphoma pipeline drugs?
- Which company is conducting major trials for Non-Hodgkin’s lymphoma drugs?
- Which companies/institutions are involved in Non-Hodgkin’s lymphoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in non-Hodgkin’s lymphoma?
Reasons To Buy This Report
The Non-Hodgkin’s Lymphoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for non-Hodgkin’s lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Non-Hodgkin’s lymphoma collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share